DIANA for diagnostics

Application

DIANA is used for a sensitive detection of active-form of protein (e.g. onco-marker) in blood or other clinical samples.

It offers superior sensitivity and selectivity with very wide dynamic range and very low amount of sample required. 

Detection kits are being developed, which will be composed of antibody coated 96- well plates, detection probe, target protein standard and buffers. Such kits could be CE IVD certified to allow use in clinical diagnostic facilities. DIANA can be also used in R&D laboratory setting, in experiments where other assays are not sensitive enough to quantify the target proteins.

Overview presentation – DIANA for diagnostics

DIANA diagnostic assay-Overview-170328
 

 

Advantages

Methods currently used for enzyme detection and for inhibitor screening suffer from low sensitivity, low reliability and narrow range. DIANA assay overcomes these limitations and provides clear advantages in its both areas of application. In diagnostics, the major benefits are:
  • Ultra-high sensitivity – up to zeptomolar (10-21 M) amounts are detected
  • Very broad dynamic range – up to 7-logs
  • Very low background – lack of antibody interference and non-specific binding
  • High selectivity for active form of the target – validation by titration with free inhibitor possible
  • Robustness – proteins can be quantified in various biological samples (incl. blood serum)
  • Easy protocol – suitable for detection kit format
  • High level of reproducibility – suitable for CE IVD

Limit of detection of 100 ag of recombinant protein (1 x 10-21 moles) or ~ 0.001 ng/ml PSMA in a 1 µl human serum sample (about 4 orders of magnitude more sensitive than ELISA assay)

High correlation between PSMA quantification using DIANA and our ELISA assay (no commercial ELISA available) has been demonstrated

Experimental protocol

  • 4 step protocol easy to implement in most laboratories
  • Can be completed within 2 hours at room temperature (with no critical time- or temperature- dependent steps)

Portfolio of clinically relevant protein targets

Detection assay developed:

  • Prostate Specific Membrane Antigen (PSMA)
  • Carbonic anhydrase 9 (CA-IX)
  • Fibroblast activating protein (FAP)

R&D pipeline: 

  • Carbonic anhydrase XII
  • Gingipains from Porphyromonas gingivalis

Custom assay development

Assay can be promptly developed on demand to majority of relevant protein targets - potential for collaborative projects

CE IVD compatible

CE IVD certification possible to allow use in clinical diagnostics - potential for collaboration with partners

Interested in using DIANA to detect your protein of interest?

  • Please do not hesitate to reach to us to discuss details